Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Acinetobacter Infections HELP
Based on 2,778 articles published since 2010

These are the 2778 published articles about Acinetobacter Infections that originated from Worldwide during 2010-2020.
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline Task force on management and prevention of Acinetobacter baumannii infections in the ICU. 2015

Garnacho-Montero, José / Dimopoulos, George / Poulakou, Garyphallia / Akova, Murat / Cisneros, José Miguel / De Waele, Jan / Petrosillo, Nicola / Seifert, Harald / Timsit, Jean François / Vila, Jordi / Zahar, Jean-Ralph / Bassetti, Matteo / Anonymous7010844. ·Unidad Clínica de Cuidados Intensivos, Instituto de Biomedicina de Sevilla (IBIS), Hospital Universitario Virgen del Rocío, Seville, Spain. jgarnachom@gmail.com. · Department of Critical Care, University Hospital ATTIKON, Medical School, University of Athens, Athens, Greece. · 4th Department of Internal Medicine, Athens University School of Medicine, Attikon University General Hospital, Athens, Greece. · Department of Infectious Diseases, Hacettepe University School of Medicine, Ankara, Turkey. · Unidad Clínicia de Enfermedades Infecciosas, Microbiología y Preventiva, Instituto de Biomedicina de Sevilla (IBIS), Hospital Universitario Virgen del Rocío, Seville, Spain. · Department of Critical Care Medicine, Ghent University Hospital, De Pintelaan 185, 9000, Ghent, Belgium. · 2nd Infectious Disease Division, National Institute for Infectious Diseases 'L. Spallanzani', Rome, Italy. · Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, Cologne, Germany. · German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Bonn, Germany. · Medical and Infectious Diseases ICU, Bichat Hospital, 75018, Paris, France. · University Paris-Diderot - Inserm U1137 - IAME, 75018, Paris, France. · Department of Clinical Microbiology, CDB, Hospital Clínic, School of Medicine, University of Barcelona, Centre for International Health Research, (CRESIB-Hospital Clínic), Barcelona, Spain. · Unité de Prévention et de Lutte Contre les Infections Nosocomiales, Université d'Angers, Centre Hospitalo-universitaire d'Angers, Angers, France. · Infectious Diseases Clinic, Santa Maria Misericordia University Hospital, Udine, Italy. ·Intensive Care Med · Pubmed #26438224.

ABSTRACT: INTRODUCTION: Acinetobacter baumannii constitutes a dreadful problem in many ICUs worldwide. The very limited therapeutic options available for these organisms are a matter of great concern. No specific guidelines exist addressing the prevention and management of A. baumannii infections in the critical care setting. METHODS: Clinical microbiologists, infectious disease specialists and intensive care physicians were invited by the Chair of the Infection Section of the ESICM to participate in a multidisciplinary expert panel. After the selection of clinically relevant questions, this document provides recommendations about the use of microbiological techniques for identification of A. baumannii in clinical laboratories, antibiotic therapy for severe infections and recommendations to control this pathogen in outbreaks and endemic situations. Evidence supporting each statement was graded according to the European Society of Clinical Microbiology and Infection Diseases (ESCMID) grading system. RESULTS: Empirical coverage of A. baumannii is recommended in severe infections (severe sepsis or septic shock) occurring during an A. baumannii outbreak, in an endemic setting, or in a previously colonized patient. For these cases, a polymyxin is suggested as part of the empirical treatment in cases of a high suspicion of a carbapenem-resistant (CR) A. baumannii strain. An institutional program including staff education, promotion of hand hygiene, strict contact and isolation precautions, environmental cleaning, targeted active surveillance, and antimicrobial stewardship should be instituted and maintained to combat outbreaks and endemic situations. CONCLUSIONS: Specific recommendations about prevention and management of A. baumannii infections in the ICU were elaborated by this multidisciplinary panel. The paucity of randomized controlled trials is noteworthy, so these recommendations are mainly based on observational studies and pharmacodynamics modeling.

2 Editorial A formidable foe: carbapenem-resistant Acinetobacter baumannii and emerging nonantibiotic therapies. 2018

Watkins, Richard R. ·a Division of Infectious Diseases , Cleveland Clinic Akron General , Akron , OH , USA. · b Department of Internal Medicine , Northeast Ohio Medical University , Rootstown , Ohio , USA. ·Expert Rev Anti Infect Ther · Pubmed #30024320.

ABSTRACT: -- No abstract --

3 Editorial Prevalence of Acinetobacter baumannii strains expressing the Type 6 secretion system in patients with bacteremia. 2017

Repizo, Guillermo D. ·a Instituto de Biologia Molecular y Celular de Rosario (IBR, CONICET), Departamento de Microbiologia , Facultad de Ciencias Bioquimicas y Farmaceuticas, Universidad Nacional de Rosario , Rosario , Argentina. ·Virulence · Pubmed #28650701.

ABSTRACT: -- No abstract --

4 Editorial The effect of ISAba1-mediated adeN gene disruption on Acinetobacter baumannii pathogenesis. 2017

Oh, Man Hwan / Choi, Chul Hee / Lee, Je Chul. ·a Department of Nanobiomedical Science , Dankook University , Cheonan , South Korea. · b Department of Microbiology and Medical Sciences , Chungnam National University, School of Medicine , Daejeon , South Korea. · c Department of Microbiology , Kyungpook National University School of Medicine , Daegu , South Korea. ·Virulence · Pubmed #28598246.

ABSTRACT: -- No abstract --

5 Editorial The influence of two-partner secretion systems on the virulence of Acinetobacter baumannii. 2017

Bigot, Sarah / Salcedo, Suzana P. ·a Molecular Microbiology and Structural Biochemistry , University of Lyon and CNRS , Lyon , France. ·Virulence · Pubmed #28118093.

ABSTRACT: -- No abstract --

6 Editorial Colistin resistance - is this pushing us over the edge into the abyss of pan-resistance? 2016

Amyes, Sebastian G B. ·Medical Microbiology, College of Medicine and Veterinary Medicine, University of Edinburgh, 49 Little France Crescent, Edinburgh EH16 4SB, UK. Electronic address: s.g.b.amyes@ed.ac.uk. ·Int J Infect Dis · Pubmed #27497952.

ABSTRACT: -- No abstract --

7 Editorial The evolving threat of carbapenem-resistant infections after liver transplantation: The case of Acinetobacter baumannii. 2016

Pereira, Marcus R / Uhlemann, Anne-Catrin. ·Department of Medicine, Division of Infectious Diseases, Columbia University Medical Center, New York. ·Liver Transpl · Pubmed #26934673.

ABSTRACT: -- No abstract --

8 Editorial Acinetobacter baumannii virulence determinants involved in biofilm growth and adherence to host epithelial cells. 2016

Zarrilli, Raffaele. ·a Department of Public Health , University of Naples "Federico II" , Naples , Italy. ·Virulence · Pubmed #26856342.

ABSTRACT: -- No abstract --

9 Editorial Use of adjuvants in the treatment of Acinetobacter baumannii. 2016

Pachón-Ibáñez, María Eugenia / Smani, Younes / Pachón, Jerónimo. ·a Clinical Unit of Infectious Diseases, microbiology, and Preventive Medicine , Institute of Biomedicine of Seville (IBiS), University Hospital Virgen del Rocío/CSIC/University of Seville , Seville , Spain. ·Expert Rev Anti Infect Ther · Pubmed #26620637.

ABSTRACT: The current antibiotic crisis to treat infections by Acinetobacter baumannii is linked with the increase of antimicrobial resistance and the lack of development of new antimicrobial drugs. For this reason, new alternatives for the treatment and control of infections by A. baumannii are necessary. Several studies have reported the effect of adjuvants to restore the efficacy of existing antimicrobial agents. Herein, we analyzed the main results on the development of adjuvant drugs, as monotherapy or in combination therapy with existing antimicrobial agents, which have shown promising results in vitro and in vivo. However, caution is needed and further extensive in vivo studies have to be performed to confirm the potential use of these adjuvants as true therapeutic alternatives.

10 Editorial The road forward in the management of Acinetobacter infections in the ICU. 2015

Niederman, Michael S / Kollef, Marin H. · ·Intensive Care Med · Pubmed #26499480.

ABSTRACT: -- No abstract --

11 Editorial Photo Quiz: A 76-Year-Old with Community-Acquired Pneumonia. 2015

Ko, Karrie K K / Lapperre, Therese S / Koh, T H. ·Department of Pathology, Singapore General Hospital, Outram Park, Singapore karrie.ko@mohh.com.sg. · Department of Respiratory and Critical Care Medicine, Singapore General Hospital, Outram Park, Singapore. · Department of Pathology, Singapore General Hospital, Outram Park, Singapore. ·J Clin Microbiol · Pubmed #26286950.

ABSTRACT: -- No abstract --

12 Editorial Acinetobacter baumannii as an underestimated pathogen in veterinary medicine. 2015

Han van der Kolk, J H. ·a Department of Clinical Veterinary Medicine, Swiss Institute for Equine Medicine (ISME), Vetsuisse Faculty , University of Bern and Agroscope , Switzerland. ·Vet Q · Pubmed #26241405.

ABSTRACT: -- No abstract --

13 Editorial Combination Therapy for Extreme Drug-Resistant Acinetobacter baumannii: Ready for Prime Time? 2015

Spellberg, Brad / Bonomo, Robert A. ·Division of Infectious Diseases, Keck School of Medicine at USC and the Los Angeles County-USC Medical Center, Los Angeles, CA Department of Medicine, Department of Pharmacology, Department of Molecular Biology and Microbiology, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Case Western Reserve University, Cleveland, OH. ·Crit Care Med · Pubmed #25978159.

ABSTRACT: -- No abstract --

14 Editorial Editorial commentary: the new Acinetobacter equation: hypervirulence plus antibiotic resistance equals big trouble. 2015

Paterson, David L / Harris, Patrick N A. ·University of Queensland Centre for Clinical Research, Royal Brisbane and Women's Hospital Campus, Australia. ·Clin Infect Dis · Pubmed #25824816.

ABSTRACT: -- No abstract --

15 Editorial Editorial commentary: Polymyxin-resistant Acinetobacter baumannii: urgent action needed. 2015

Pogue, Jason M / Cohen, David A / Marchaim, Dror. ·Department of Pharmacy Services, Sinai-Grace Hospital, Detroit Medical Center, Wayne State University School of Medicine, Michigan. · Unit of Infectious Diseases, Assaf Harofeh Medical Center, Zerifin. · Unit of Infectious Diseases, Assaf Harofeh Medical Center, Zerifin Sackler School of Medicine, Tel-Aviv University, Israel. ·Clin Infect Dis · Pubmed #25632011.

ABSTRACT: -- No abstract --

16 Editorial Clinical implications of glycoproteomics for Acinetobacter baumannii. 2015

Kinsella, Rachel L / Scott, Nichollas E / Feldman, Mario F. ·University of Alberta, Biological Sciences, Edmonton, AB, Canada. ·Expert Rev Proteomics · Pubmed #25496064.

ABSTRACT: The opportunistic human pathogen Acinetobacter baumannii persists in the healthcare setting because of its ability to survive exposure to various antimicrobial and sterilization agents. A. baumannii's ability to cause multiple infection types complicates diagnosis and treatment. Rapid detection of A. baumannii infections would likely improve treatment outcomes. Recently published Acinetobacter glycoproteomic data show the prevalence of O-linked glycoproteins, suggesting the possibility for an O-glycan-based detection technology. O-glycan biosynthesis is required for protein glycosylation and capsular polysaccharide production in A. baumannii. Recent publications demonstrate key roles for protein glycosylation and capsular polysaccharide in the pathogenicity of A. baumannii. Targeted antimicrobial development against O-glycan biosynthesis may produce new effective treatment options for A. baumannii infections. Here, we discuss how the data gathered through Acinetobacter glycoproteomics can be used to develop technologies for rapid diagnosis and reveal potential antimicrobial targets. In addition, we consider the efficacy of glycoconjugate vaccine development against A. baumannii.

17 Editorial The deadly impact of extreme drug resistance in Acinetobacter baumannii. 2014

Spellberg, Brad / Bonomo, Robert A. ·Division of General Internal Medicine, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA; and, Division of General Internal Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA Department of Medicine, Department of Pharmacology; and, Department of Molecular Biology and Microbiology, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Case Western Reserve University, Cleveland, OH. ·Crit Care Med · Pubmed #24736340.

ABSTRACT: -- No abstract --

18 Editorial The guest who would not leave. 2013

Wortmann, Glenn. ·Infectious Diseases Section, MedStar Washington Hospital Center, Washington, DC. ·Crit Care Med · Pubmed #24275395.

ABSTRACT: -- No abstract --

19 Editorial Community-acquired pneumonia infections by Acinetobacter baumannii: how does alcohol impact the antimicrobial functions of macrophages? 2013

Eugenin, Eliseo A. · ·Virulence · Pubmed #23863602.

ABSTRACT: -- No abstract --

20 Editorial Editorial commentary: rifampicin plus colistin in the era of extensively drug-resistant Acinetobacter baumannii infections. 2013

Gauthier, Timothy P. · ·Clin Infect Dis · Pubmed #23616496.

ABSTRACT: -- No abstract --

21 Editorial Treating multidrug-resistant Acinetobacter baumannii infection by blocking its virulence factors. 2013

López-Rojas, Rafael / Smani, Younes / Pachón, Jerónimo. · ·Expert Rev Anti Infect Ther · Pubmed #23458763.

ABSTRACT: -- No abstract --

22 Editorial Incomplete network for survivors of catastrophic illness after release from ICUs. 2013

Vitacca, Michele / Nava, Stefano. · ·Respir Care · Pubmed #23359729.

ABSTRACT: -- No abstract --

23 Editorial Editor's note. 2013

Bradley, John S. · ·Pediatr Infect Dis J · Pubmed #23328820.

ABSTRACT: -- No abstract --

24 Editorial Ventilator-associated pneumonia: the answer depends on the question being asked. 2013

Argent, Andrew C / Morrow, Brenda M. · ·Pediatr Crit Care Med · Pubmed #23295842.

ABSTRACT: -- No abstract --

25 Editorial Aerosolized antibiotic therapy: a forward aerial assault or forced contingency for ventilator-associated pneumonia? 2012

Moore, Molly E / Mueller, Eric W. · ·Respir Care · Pubmed #22867643.

ABSTRACT: -- No abstract --